POINTER
Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention: The POINTER Imaging Ancillary Study
Clinical Question
Does a structured, high-intensity multidomain lifestyle intervention affect brain imaging biomarkers of Alzheimer disease, cerebrovascular disease, and neurodegeneration, and which subgroups benefit most cognitively?
Bottom Line
A 2-year high-intensity multidomain lifestyle intervention did not alter Aβ, tau, hippocampal volume, or white matter hyperintensity trajectories, but older adults with lower baseline hippocampal volume derived greater cognitive benefit from the structured versus self-guided intervention — supporting risk-stratified use of intensive lifestyle interventions rather than expecting biomarker modification.
Major Points
- In 983 imaging participants, structured vs self-guided multidomain intervention did NOT differ on any of the 4 primary imaging outcomes (global Aβ, ERC tau, hippocampal volume, WMH volume) over 2 years
- Intervention effects on cognition were NOT associated with or moderated by baseline Aβ status or Aβ accumulation
- Negative association between change in ERC tau and change in global cognition seen in the self-guided group was attenuated in the structured group (difference 0.289; 95% CI 0.029-0.550; interaction P=.03)
- Lower baseline hippocampal volume predicted greater cognitive benefit from the structured intervention (0.077 SD; 95% CI 0.022-0.132) vs no benefit in higher HC (0.002 SD; interaction P=.03)
- A high-intensity lifestyle intervention works via non-AD-specific mechanisms in older adults with neurodegeneration risk markers, rather than by modifying AD biomarker trajectories
Design
Study Type: Randomized clinical trial (imaging ancillary of US POINTER phase 3, single-blind trial)
Randomization: 1
Blinding: Single-blind
Allocation: Randomly assigned to structured or self-guided multidomain intervention
Enrollment Period: May 2019 to March 2023 (imaging enrollment starting August 2020); final follow-up May 14, 2025
Follow-up Duration: 2 years (MRI at baseline, 12 months, 24 months; Aβ-PET and tau-PET at baseline and 24 months)
Centers: 5
Countries: United States
Sample Size: 983
Analyzed: 983
Analysis: Intent-to-treat; linear mixed-effects models; two-tailed type I error 0.05 with no multiple comparison correction; prespecified sensitivity analyses (removing scanner-change participants and 10% worst out-of-window scans); R version 4.5.0
Registration: NCT03688126
Inclusion Criteria
- Age 60-79 years at enrollment
- Sedentary lifestyle
- Suboptimal diet
- At least 2 additional risk criteria for cognitive decline
- No objective cognitive impairment but increased risk based on lifestyle factors, cardiovascular disease, and family history
- No contraindications for neuroimaging (MRI and PET)
- Enrolled in the US POINTER parent trial
Exclusion Criteria
- Contraindications for neuroimaging
- Objective cognitive impairment (dementia)
Arms
| Field | Structured multidomain lifestyle intervention | Control |
|---|---|---|
| N | 516 | 467 |
| Intervention | High-intensity, structured multidomain intervention with greater accountability emphasizing physical activity, cognitive activity, healthy nutrition, social engagement, and cardiovascular health monitoring | Lower-intensity self-guided multidomain intervention emphasizing physical activity, cognitive activity, healthy nutrition, social engagement, and cardiovascular health monitoring |
| Duration | 2 years | 2 years |
Outcomes
| Outcome | Type | Control | Intervention | HR / OR / RR | P-value |
|---|---|---|---|---|---|
| Four primary imaging outcomes (global Aβ burden, ERC tau burden, hippocampal volume, WMH volume) and the primary cognitive measure (global cognitive composite) | Primary | No significant longitudinal change differing from structured arm on any imaging outcome or cognitive composite | No significant differences from self-guided arm on any imaging outcome or cognitive composite | No intervention group differences in longitudinal cognitive or imaging outcomes | Not significant for group differences |
| Association between change in ERC tau and change in global cognition, by intervention arm | Secondary | Difference in association 0.289 | Interaction P = .03 | ||
| Baseline hippocampal volume as moderator of intervention effect on cognition | Secondary | Lower HC: 0.077 SD; Higher HC: 0.002 SD | Interaction P = .03 | ||
| Aβ status/accumulation as moderator of intervention effects | Secondary | Not significant | |||
| Severe adverse events | Safety | None reported across all MRI and PET scanning sessions | |||
| Procedure-related adverse events | Safety | Structured: 3 · Self-guided: 1 · Total: 4 | |||
| Nonurgent incidental findings | Safety | Structured: 46 · Self-guided: 48 · Total: 94 | |||
| Urgent incidental findings | Safety | Structured: 2 · Self-guided: 3 · Total: 5 | |||
| Severe AEs | Adverse | None | |||
| Procedure-related AEs | Adverse | 4 total (3 structured, 1 self-guided) | |||
| Nonurgent incidental findings | Adverse | 94 total | |||
| Urgent incidental findings | Adverse | 5 total (2 structured, 3 self-guided) | |||
Subgroup Analysis
Five prespecified baseline subgroups analyzed: age, sex, APOE ε4 status, prevalent cardiovascular disease with Framingham Risk Score, and baseline cognitive status. Additional at-risk imaging subgroups defined by tertiles of HC and WMH volume adjusted for intracranial volume, age, and sex. Lower baseline HC volume identified participants with greater cognitive benefit from the structured intervention (interaction P=.03). Baseline Aβ status did not moderate intervention effects.
Criticisms
- No multiple comparison correction across analyses (two-tailed α=0.05)
- 2-year follow-up may be too short to detect biomarker trajectory changes from a lifestyle intervention
- Baseline imbalance in ERC tau among Aβ+ participants (higher in structured group)
- Self-guided arm still received a multidomain intervention rather than a true no-treatment control, limiting inference about absolute intervention effects on biomarkers
- Interaction findings (HC volume, ERC tau) were exploratory secondary analyses with modest interaction P values (.03) and could be chance findings
Based on: POINTER (JAMA Neurology, 2026)
Authors: Harrison TM, Harvey DJ, Chadwick T, ..., Landau SM
Citation: JAMA Neurol. 2026;83(6):521-529. doi:10.1001/jamaneurol.2026.0832
Content summarized and formatted by NeuroTrials.ai.